OBJECTIVES: To assess cost-effectiveness of adalimumab versus standard care (SC) for treating patients with severely active Crohn’s disease (CD) in Germany from a societal perspective. Additionally, cost-per-remitter for adalimumab was estimated and compared with infliximab 5mg/kg maintenance therapy.  METHODS: To compare adalimumab to SC, a 4-disease-state clinical model (ie, remission, moderate, severe, very severe) based on the Crohn’s Disease Activity Index (CDAI) was constructed tracking patients over their lifetimes. The model estimated direct costs, indirect costs, and quality-adjusted life-years (QALYs) from the German societal perspective. Efficacy inputs for adalimumab were based on actual observations from CHARM (Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission Maintenance). Using data from CLASSIC I (Clinical Assessment of Adalimumab Safety and Efficacy Studied as Induction Therapy in Crohn’s Disease), a regression model was used to predict efficacy of SC. Direct/indirect costs and utility inputs were derived from public sources and literature. To compare adalimumab to infliximab, cost-per-remitter was estimated by dividing costs by the percentage of patients in remission on a yearly basis. Remission rates of adalimumab and infliximab upon baseline matching adjustment for patients with moderate-to-severe CD came from CHARM and ACCENT I (A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen), respectively. RESULTS: The incremental costs per QALY gained for adalimumab versus SC were €37,270 (2012 Euro) over a lifetime horizon in the base case. One-way sensitivity analyses varying key parameters produced incremental costs per QALY gained ranging from €23,011–€51,528 when compared with SC. An average of 47.2% adalimumab-treated and 37.1% infliximab-treated patients were in remission yearly. The corresponding cost-per-remitter was €54,823 for adalimumab and €88,506 for infliximab. CONCLUSIONS: Adalimumab appears to be cost-effective compared with SC for treating patients with severely active CD. The cost-per-remitter for maintenance therapy was less for adalimumab than for infliximab.